188 related articles for article (PubMed ID: 38561964)
1. The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances.
Khorasani ABS; Hafezi N; Sanaei MJ; Jafari-Raddani F; Pourbagheri-Sigaroodi A; Bashash D
Cell Biochem Funct; 2024 Apr; 42(3):e3998. PubMed ID: 38561964
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials.
Davoodi-Moghaddam Z; Jafari-Raddani F; Delshad M; Pourbagheri-Sigaroodi A; Bashash D
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15293-15310. PubMed ID: 37594532
[TBL] [Abstract][Full Text] [Related]
3. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
4. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
Brufsky AM
Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
[TBL] [Abstract][Full Text] [Related]
5. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.
Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A
Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
7. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
Zhu K; Wu Y; He P; Fan Y; Zhong X; Zheng H; Luo T
Cells; 2022 Aug; 11(16):. PubMed ID: 36010585
[TBL] [Abstract][Full Text] [Related]
10. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
Shan KS; Bonano-Rios A; Theik NWY; Hussein A; Blaya M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396649
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies.
Mohite R; Doshi G
Curr Cancer Drug Targets; 2024; 24(3):231-244. PubMed ID: 37526459
[TBL] [Abstract][Full Text] [Related]
12. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
Narayanankutty A
Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
[TBL] [Abstract][Full Text] [Related]
13. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK).
Huang X; You L; Nepovimova E; Psotka M; Malinak D; Valko M; Sivak L; Korabecny J; Heger Z; Adam V; Wu Q; Kuca K
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2237209. PubMed ID: 37489050
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
17. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
[TBL] [Abstract][Full Text] [Related]
18. Recent clinical advances in PI3K inhibitors on colorectal cancer.
Zhu M; Jin Q; Xin Y
Pharmazie; 2021 Dec; 76(12):568-573. PubMed ID: 34986950
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
20. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
Lauring J; Park BH; Wolff AC
J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
